BioCryst Pharmaceuticals | BCRX - 债务



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.76B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


债务 更改 日
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Chugai Pharma JPY 14.11B 1.93B 2022-12
Daiichi Sankyo JPY 201.14B 99.81B 2025-09
DBV Technologies USD 8.59M 295K 2025-09
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 17.75B 396M 2025-09
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novavax USD 233.31M 4.23M 2024-09
PTC Therapeutics USD 286.94M 2.42B 2026-03
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Roche Holding CHF 33.03B 1.41B 2025-06
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.99B 44M 2026-03